Comments
Natco Pharma Ltd has obtained approval for marketing its Rizatriptan Benzoate (Maxalt-MLD) orally disintegrating tablets in the US market.
The drug is used in the treatment of migraine headache with or without warning signs that occur prior to the onset of headache.
The Hyderabad-based company had already commenced shipments of the product which was being launched by its marketing partner, Breckenridge Pharmaceuticals.
Natco estimates the market to be around $250 million (before generic launch – as of December 31, 2012).
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.